Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Metabolic reprogramming during hyperammonemia targets mitochondrial function and postmitotic senescence
Avinash Kumar, Nicole Welch, Saurabh Mishra, Annette Bellar, Rafaella Nasciemento Silva, Ling Li, Shashi Shekhar Singh, Mary Sharkoff, Alexis Kerr, Aruna Kumar Chelluboyina, Jinendiran Sekar, Amy H. Attaway, Charles Hoppel, Belinda Willard, Gangarao Davuluri, Srinivasan Dasarathy
Avinash Kumar, Nicole Welch, Saurabh Mishra, Annette Bellar, Rafaella Nasciemento Silva, Ling Li, Shashi Shekhar Singh, Mary Sharkoff, Alexis Kerr, Aruna Kumar Chelluboyina, Jinendiran Sekar, Amy H. Attaway, Charles Hoppel, Belinda Willard, Gangarao Davuluri, Srinivasan Dasarathy
View: Text | PDF
Research Article Cell biology Hepatology

Metabolic reprogramming during hyperammonemia targets mitochondrial function and postmitotic senescence

  • Text
  • PDF
Abstract

Ammonia is a cytotoxic metabolite with pleiotropic molecular and metabolic effects, including senescence induction. During dysregulated ammonia metabolism, which occurs in chronic diseases, skeletal muscle becomes a major organ for nonhepatocyte ammonia uptake. Muscle ammonia disposal occurs in mitochondria via cataplerosis of critical intermediary metabolite α-ketoglutarate, a senescence-ameliorating molecule. Untargeted and mitochondrially targeted data were analyzed by multiomics approaches. These analyses were validated experimentally to dissect the specific mitochondrial oxidative defects and functional consequences, including senescence. Responses to ammonia lowering in myotubes and in hyperammonemic portacaval anastomosis rat muscle were studied. Whole-cell transcriptomics integrated with whole-cell, mitochondrial, and tissue proteomics showed distinct temporal clusters of responses with enrichment of oxidative dysfunction and senescence-related pathways/proteins during hyperammonemia and after ammonia withdrawal. Functional and metabolic studies showed defects in electron transport chain complexes I, III, and IV; loss of supercomplex assembly; decreased ATP synthesis; increased free radical generation with oxidative modification of proteins/lipids; and senescence-associated molecular phenotype–increased β-galactosidase activity and expression of p16INK, p21, and p53. These perturbations were partially reversed by ammonia lowering. Dysregulated ammonia metabolism caused reversible mitochondrial dysfunction by transcriptional and translational perturbations in multiple pathways with a distinct skeletal muscle senescence-associated molecular phenotype.

Authors

Avinash Kumar, Nicole Welch, Saurabh Mishra, Annette Bellar, Rafaella Nasciemento Silva, Ling Li, Shashi Shekhar Singh, Mary Sharkoff, Alexis Kerr, Aruna Kumar Chelluboyina, Jinendiran Sekar, Amy H. Attaway, Charles Hoppel, Belinda Willard, Gangarao Davuluri, Srinivasan Dasarathy

×

Figure 8

Reduction in ATP content and increased mitochondrial free radicals and oxidative modifications reversed by ammonia lowering.

Options: View larger image (or click on image) Download as PowerPoint
Reduction in ATP content and increased mitochondrial free radicals and o...
(A) Total ATP content in murine C2C12 myotubes treated with 10 mM ammonium acetate for 24 hours (AmAc) without or with withdrawal of ammonium acetate for 24 hours (WD) and untreated myotubes (UnT). (B) ATP content in gastrocnemius muscle from hyperammonemic portacaval anastomosis (PCA) or sham-operated control (Sham) rats treated with or without L-ornithine-L-aspartate and rifaximin (LOLA). (C) Flow cytometry–gated DCFDA fluorescence and percentage of DCFDA fluorescent cells in differentiated C2C12 myotubes treated with AmAc and WD. (D) Flow cytometry–derived fluorescence and percentage of cells stained by MitoSOX in response to AmAc and WD in differentiated myotubes. Representative immunoblots and densitometry for (E and F) carbonylated proteins and (G and H) lipid peroxidation quantified by thiobarbituric acid reactive substances (TBARS) in UnT, AmAc, and WD myotubes and in gastrocnemius muscle from PCA or Sham rats treated with or without LOLA. (I) Representative immunoblots and densitometry of citrate synthase (CS) and voltage dependent anion channel (VDAC) in UnT, AmAc, and WD myotubes. (J) Representative immunoblots and densitometry of CS and VDAC in gastrocnemius muscle from PCA or Sham rats treated with or without LOLA. All data expressed as mean ± SD from at least 3 biological replicates for experiments in myotubes and at least 5 rats in each group. *P < 0.05; **P < 0.01; ***P < 0.001 using 1-way ANOVA followed by Bonferroni’s post hoc comparison tests.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts